Chúng tôi luôn giới thiệu các thử nghiệm lâm sàng trong toàn bộ hệ thống quốc tế của chúng tôi. Nếu bạn không tìm thấy cái mà bạn đang tìm kiếm thì hãy mạnh dạn trao đổi với bác sĩ của bạn, hoặc contact us here.
Tìm một chương trình thử nghiệm
Tại Icon, chúng tôi cung cấp các thử nghiệm lâm sàng cho một số thể loại u và các rối loạn huyết học, cho phép bệnh nhân được tiếp cận với các điều trị mới và tiên tiến. Hãy tìm một thử nghiệm có thể thích hợp với bạn.
Sử dụng chức năng tìm kiếm dưới đây để tìm một thử nghiệm lâm sàng có thể phù hợp với bạn và bệnh lý ung thư của bạn.
IL Believe
A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Locations
Farrer Park
Diagnosis
Advanced solid tumours, Skin cancer – melanoma, Cervical cancer, Lung cancer
Open for recruitment
Xem Trial
DeLLphi-306
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Locations
Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
Xem Trial
pionERA
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Locations
Gleneagles, Farrer Park
Diagnosis
Breast cancer
Open for recruitment
Xem Trial
INAVO122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
Xem Trial
CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
Xem Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
Xem Trial
INBRX-106
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Locations
Farrer Park, Mount Alvernia
Diagnosis
Advanced solid tumours
Open for recruitment
Xem Trial
Trofuse-010
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Locations
Mount Alvernia
Diagnosis
Breast cancer
Open for recruitment
Xem Trial
Lunar-2
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Locations
Farrer Park, Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
Xem Trial
REZILIENT3
Randomized, Controlled, Open-label, Phase 3, Global Multi- Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Locations
Farrer Park
Diagnosis
Lung cancer
Open for recruitment
Xem Trial
There are no clinical trials currently available